Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tusamitamab ravtansine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tusamitamab ravtansine overview
Tusamitamab ravtansine is under development for the treatment of solid tumors including metastatic non- squamous non-small cell lung cancer, colorectal cancer, non-squamous non-small cell lung cancer (NSCLC), small cell lung cancer, gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, esophago-gastric junction adenocarcinoma, cholangiocarcinoma, epithelial ovarian cancer, endometrial adenocarcinoma, metastatic breast cancer (mBC), triple-negative breast cancer (TNBC) and metastatic pancreatic adenocarcinoma (mPAC). The drug candidate is administered through intravenous route as a solution concentrate. The drug candidate targets carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5 or CD66e). It is a new molecular entity (NME).
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of Tusamitamab ravtansine’s drug-specific PTSR and LoA scores, buy the report here.